Form 4: Stoke Therapeutics Director Converts RSUs to Common Stock

Arthur A. Levin, a Director at Stoke Therapeutics, acquired 1,211 shares of common stock through the vesting and conversion of Restricted Stock Units.

Summary

• Arthur A. Levin, a Director of Stoke Therapeutics, Inc., acquired 1,211 shares of the company's common stock.
• This acquisition occurred on September 30, 2025, through the vesting and conversion of Restricted Stock Units (RSUs).
• The transaction price for the acquired common stock was $0, reflecting the nature of RSU conversion.
• Following this transaction, Mr. Levin directly holds 3,631 shares of common stock.
• Additionally, Mr. Levin indirectly holds 17,979 shares of common stock through the Butler-Levin Revocable Trust.
• After the conversion, Mr. Levin continues to directly hold 1,211 derivative securities, specifically Restricted Stock Units.
• The RSUs vest quarterly on the last day of March, June, September, and December, contingent on continued service.
• The expiration date for the RSU award is December 31, 2025.

Sentiment

Score: 6

Explanation: The transaction is a routine vesting and conversion of Restricted Stock Units, indicating continued alignment of a director's interests with shareholders. It is a standard compensation event and does not signal significant new information.

Positives

• Director Arthur A. Levin's acquisition of 1,211 common shares through RSU vesting indicates continued alignment of management interests with shareholders.
• The ongoing vesting schedule suggests continued commitment of the director to the company.

Future Outlook

Remaining Restricted Stock Units will continue to vest quarterly on the last day of March, June, September, and December, subject to the reporting person's continued service to the issuer through each vesting date.

Industry Context

This filing represents a routine insider transaction related to equity compensation, common in the biotechnology or pharmaceutical industry for retaining and incentivizing key personnel like directors. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• Equity compensation, including Restricted Stock Units (RSUs), is a standard practice across various industries, particularly in high-growth sectors like biotechnology, to align executive and director incentives with shareholder value.
• The vesting schedule (quarterly over a period) is typical for such awards. No specific comparable companies or projects are mentioned in the filing to allow for a detailed comparison.

Related Party Transactions

• The vesting and conversion of Restricted Stock Units are part of the director's compensation package, which is a standard related-party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director may be viewed positively as it aligns interests, but the impact is minimal given the routine nature and size of the transaction relative to total shares outstanding.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• Remaining Restricted Stock Units will continue to vest quarterly on the last day of March, June, September, and December.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting and conversion of Restricted Stock Units into common stock by a director. Such events are typically pre-scheduled compensation activities and do not usually provide new material information that would significantly alter the investment thesis for Stoke Therapeutics. While it indicates continued alignment of management interests, it is not a strong signal for a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific filing.

Keywords

Stoke Therapeutics, STOK, Arthur A. Levin, Form 4, Insider Transaction, Restricted Stock Units, RSU conversion, Common Stock, Director ownership, Equity compensation